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ABSTRACT: Plasminogen activator inhibitor type 1 (PAI-1) regulates the ﬁbrinolysis pathway by
inhibiting the protease activity of plasminogen activators. PAI-1 works in concert with vitronectin (VN),
an extracellular protein that aids in localization of active PAI-1 to tissues. The Peterson laboratory
demonstrated that Cu(II) and other transition metals modulate the stability of PAI-1, exhibiting eﬀects
that are dependent on the presence or absence of the somatomedin B (SMB) domain of VN. The study
presented here dissects the changes in molecular dynamics underlying the destabilizing eﬀects of Cu(II)
on PAI-1. We utilize backbone amide hydrogen/deuterium exchange monitored by mass spectrometry
to assess PAI-1 dynamics in the presence and absence of Cu(II) ions with and without the SMB domain
of VN. We show that Cu(II) produces an increase in dynamics in regions important for the function
and overall stability of PAI-1, while the SMB domain elicits virtually the opposite eﬀect. A mutant form
of PAI-1 lacking two N-terminal histidine residues at positions 2 and 3 exhibits similar increases in
dynamics upon Cu(II) binding compared to that of active wild-type PAI-1, indicating that the observed
structural eﬀects are not a result of coordination of Cu(II) to these histidine residues. Finally, addition
of Cu(II) results in an acceleration of the local unfolding kinetics of PAI-1 presumed to be on pathway
to the latency conversion. The eﬀect of ligands on the dynamics of PAI-1 adds another intriguing dimension to the mechanisms
for regulation of PAI-1 stability and function.

T

that is not dependent on its anti-protease activity and is linked
to cancer and inﬂammatory diseases via complex mechanisms.
PAI-1 achieves speciﬁc and rapid inhibition of serine
proteases (tPA/uPA) through a solvent-exposed loop termed
the reactive center loop (RCL)10 that contains the scissile bond
recognized as the natural protease substrate. Upon interaction
with the protease, PAI-1 traps a covalent acyl−enzyme
intermediate in a stable complex through a mechanism that
invokes a profound conformational rearrangement and
insertion of the RCL into central β-sheet A.11 Interestingly,
PAI-1 RCL insertion spontaneously occurs even in the absence
of proteases (t1/2 ∼ 1−2 h)12 to form a latent, inactive state13
(Figure 1). Thus, PAI-1 possesses inherent metastability, a
hallmark of serpin activity that drives the structural change that
traps and inactivates the protease.11 Nonetheless, few serpins
incur the structural rearrangement to latency in the absence of a
protease; this latency conversion of PAI-1 is shared with
antithrombin and, to a lesser extent, neuroserpin.14,15 The
process of latency transition is not completely understood at

he physiological processes of blood clot formation
(coagulation) and subsequent breakdown (ﬁbrinolysis)
are activated by highly speciﬁc serine protease cascades.1 The
activity of these proteases is subject to tight regulation to
maintain hemostasis. Plasminogen activator inhibitor type 1
(PAI-1) is a primary regulator of the ﬁbrinolytic pathway.2 PAI1 is a member of the serine protease inhibitor (serpin) family
and speciﬁcally inhibits tissue-type plasminogen activator (tPA)
and urokinase plasminogen activator (uPA), controlling
hemostasis, wound healing, matrix remodeling, and cell
proliferation and diﬀerentiation.3−5 Dysregulation of PAI-1
leads to numerous diseases in humans. While elevated levels of
PAI-1 result in thrombosis6 and ﬁbrosis in various tissues,
including liver, kidney, lung, and skin,3 depletion of PAI-1
results in a hyperﬁbrinolytic state characterized by mild
bleeding and impaired wound healing.7 However, PAI-1
deﬁciency and elevated levels of functional plasminogen
activators in macrophages, in tandem with altered signaling
pathways, also lead to tissue-speciﬁc cardiac ﬁbrosis.8 These
somewhat paradoxical ﬁndings illustrate an intricate regulatory
network involving PAI-1 and multiple downstream eﬀects that
result in a variety of tissue-speciﬁc pathologies.3 Furthermore,
PAI-1 regulates endothelial cell migration9 via a mechanism
© 2016 American Chemical Society
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inﬂammatory states, metabolic syndrome, and atherosclerosis.30
We aim to understand the molecular basis for the eﬀect of
metal ions on PAI-1 conformational and functional stability, as
it may play a role in these disease states. We are also interested
in determining whether changes in local dynamics due to ligand
binding inﬂuence the global conformational state of PAI-1. This
issue is of upmost importance for fully understanding the role
of serpins in disease states.
Prior studies using hydrogen/deuterium exchange monitored
by mass spectrometry (HDX-MS) have shown that wild-type
PAI-1 is highly dynamic; apart from a protected β-sheet B core,
many regions rapidly reach complete exchange.31 Ligands such
as the SMB domain of vitronectin, Mab-1 antibody, and RNA
aptamers extend the length of time PAI-1 remains active.12,32,24
Expectedly, ligand binding protects against isotopic exchange in
the binding interface, but the protected regions generally
extend beyond the binding interface.31,33 For example, binding
of the SMB domain signiﬁcantly protects against exchange in
peptides spanning hE and s1A, comprising the binding
interface. In addition, the SMB domain protects against
exchange in hB, hC, hD, s2A, hF, s3A, s5A, and hI. Thus,
SMB domain binding confers stabilization on peptides
spanning the better part of the bottom pole of the molecule.31
Furthermore, mutations that stabilize PAI-1 in the active form
(14-1b containing N150H, K154T, Q319L, and M354I
substitutions) also result in reduced dynamics, particularly in
peptides near the mutations (hF, s2C, and s6A), but also in
more remote regions (hB, hC, hE, s1A, hI, s2B, and s3B).31
Compared with the relatively stable serpins neuroserpin and α1-antitrypsin, the active form of PAI-1 is more dynamic in the
key functional regions thought to be involved in the latency
transition.31 Additionally, HDX has been used to detect partial
unfolding events within the hydrophobic core of PAI-118 that
oﬀer new insight into how PAI-1 converts from the active to
latent form.
The recently completed crystal structure (PDB entry 3Q02)
features a zinc ion bound to two N-terminal histidines (H2 and
H3) of one PAI-1 molecule and carboxylate-containing residues
(E212, D222, E350, and E242) from the gate region of a
second PAI-1 molecule, forming an asymmetric dimer interface.34 To determine whether H2 and H3 of PAI-1 coordinate
Cu(II) and mediate structural eﬀects, we have also created and
analyzed a mutant form of PAI-1 that has alanine substitutions
for the two N-terminal histidine residues (H2AH3A-PAI-1).
We hypothesize that ligands govern PAI-1 conformational
stability through ﬁne-tuning of protein dynamics. In this work,
we have investigated several unanswered questions using
hydrogen/deuterium exchange methods. Does Cu(II) binding
increase the dynamics in regions of PAI-1 tied to latency
transition? Are these regions stabilized in the presence of
Cu(II) and the SMB domain of VN? Are the eﬀects of Cu(II)
speciﬁcally targeted to the active form? Here, we have found
that Cu(II) binding increases the dynamics in structurally
correlated regions of active wild-type PAI-1 (wtPAI-1). These
regions are similar to those that have been targeted to reduce
PAI-1 dynamics and stabilize PAI-1 in the active form by
mutagenesis, addition of VN, antibodies, or aptamers. The
structurally correlated regions include the ﬂexible joint region
and shutter region, as well as hI, hB, and hC.

Figure 1. PAI-1 exists in an active and latent conformation. The active
form of PAI-1 is shown on the left (PDB entry 3Q02), and the latent
form of PAI-1 is shown on the right (PDB entry 1DVN). The RCL
(orange) acts as bait for proteases in the active form where it is
solvent-exposed; it is inserted into central B-sheet A in the latent form.
Several steps in the mechanism of the transition to the latent form
have been proposed,9 and it appears that local unfolding within key
regions is involved.14 The shutter region (green) expands, and the gate
region loops (teal) rearrange during the RCL insertion that occurs
during the latency conversion. Helix F (blue) may be displaced
temporarily during unfolding of the hydrophobic core and/or
rearrangement in the bottom half of the shutter when the RCL is
added as an additional strand in the central β-sheet. The ﬂexible joint
region (red) is an important site for PAI-1 protein−protein
interactions, including binding of the SMB domain.15 This view of
the molecule will be the standard reference orientation, with the RCLcontaining pole of PAI-1 termed the “top” and central β-sheet A
termed the “front”. The nomenclature for secondary structure is as
follows: hA−hI are α-helices A−I, respectively; s1A is strand 1 of βsheet A, s6B is strand 6 of β-sheet B, etc.

the molecular level. As an absolute minimum, the structural
rearrangement requires detachment of s1C,16 opening of the
gate region between the s3C−s4C and s3B−hG loops,13
opening of the shutter region between strands s3A and s5A,
and displacement of hF13,17 (Figure 1). Recently, transient
unfolding of the hydrophobic core of PAI-1 was documented
and proposed to play a role in the conversion to the latent
form.18 The ﬂexible joint region (hD, hE, and s1A) contains the
site of regulatory protein−protein interactions.19,20 A beneﬁt of
the metastable feature of PAI-1 is that it allows for
conformational ﬁne-tuning by diﬀerent ligands. PAI-1 associates tightly with the glycoprotein vitronectin (VN) in the
circulation, speciﬁcally at sites of injury.21 VN localizes PAI-1 to
ﬁbrin matrices and inﬂamed tissues, and it modestly stabilizes
PAI-1 in its active form (approximately 1.5-fold).22 PAI-1 also
has been shown to be stabilized by certain mutations, pH, a
high salt concentration, and aptamers.23−25
Other PAI-1 ligands, including transition metal ions, such as
Cu(II), Ni(II), and Co(II), accelerate the latency transition
(t1/2 ∼ 10−20 min). The destabilizing eﬀect of these metal ions
on PAI-1 is, however, abrogated in the presence of the
somatomedin B (SMB) domain of VN.12 Stopped-ﬂow
ﬂuorescence measurements determined a dissociation constant
of 90 nM for PAI-1 and Cu(II) ions.26 This aﬃnity is well
within the range of physiological relevance given that
micromolar Cu(II) concentrations have been measured in the
brain, cerebrospinal ﬂuid, and liver.27,28 Interestingly, imbalances in metal homeostasis29 lead to several of the same disease
states that occur due to dysfunction of serpins, most notably

■

MATERIALS AND METHODS
PAI-1 Protein Expression and Puriﬁcation. Recombinant wild-type and mutant PAI-1 proteins were produced using
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pET-24d expression plasmid DNA transformed into Escherichia
coli Rosetta 2(DE3)pLysS cells (Novagen-EMD) using the
heat-shock method. Colonies were grown on agar plates
containing kanamycin and chloramphenicol. Polymerase chain
reaction-based site-directed mutagenesis was performed using a
Quiksite mutagenesis kit (Agilent) with primers designed
(Invitrogen/Life Technologies) to incorporate triplet codons
necessary to express the desired mutations corresponding to
histidine to alanine mutations at residues 2 and 3. Mutagenesis
was conﬁrmed by DNA sequencing. Transfer of a single colony
to liquid culture was followed by growth and subculture in a
larger volume at 37 °C with shaking at 250 rpm. As the optical
density (OD600) approached 1.0 absorption unit, the temperature was reduced from 37 to 15 °C and protein expression was
induced by addition of 1 mM IPTG (Research Products
International, RPI) to the Terriﬁc Broth cell culture medium
(RPI).
Wild-type PAI-1 protein was puriﬁed with a three-column
procedure as described in ref 12: Sulfopropyl (SP) Sepharose
for cation exchange eluted with an ammonium sulfate gradient,
nickel-charged chelating Sepharose for immobilized metal
aﬃnity (IMAC) eluted with an imidazole gradient, and gel
ﬁltration (S-100) Sephacryl to separate impurities from the ﬁnal
preparation. The mutant H2A/H3A-PAI-1 form of the protein
puriﬁcation utilized a phenyl Sepharose column instead of the
IMAC step using a reverse salt gradient. Pure PAI-1 mutant and
wild-type proteins were passed over a catalytically inactive tPA
(S478A) column (Molecular innovations)35 and eluted with 1.5
M NaCl in 0.5 M sodium acetate to ensure the active
conformation was isolated for analysis. Polyacrylamide gel
electrophoresis conﬁrmed the formation of a 1:1 stoichiometric
complex of PAI-1 and tPA in stable complexes.
Vitronectin Protein Fragment Expression and Puriﬁcation. The vitronectin fragment SMB domain was produced
using the pET-32b plasmid transformed into Rosetta-gami
2(DE3)pLysS cells equipped to fold disulﬁde-bonded proteins.
The DNA sequences encoded thioredoxin protein fused Nterminally to the VN sequence along with a six-His tag, which
was connected by a region encoding a thrombin cleavage site;
this construct is denoted Trx-SMB. Transformation and colony
selection occurred as described above from agar plates
containing ampicillin and chloramphenicol. After initial growth
in medium containing tetracycline in addition to the
aforementioned antibiotics, cells were subcultured to larger
volumes at 37 °C while being shaken at 300 rpm. The
temperature was then lowered to 20 °C, and after adaptation,
the cultures were induced with 1 mM IPTG for overnight
protein expression.
Puriﬁcation involved ﬁrst isolating Trx-SMB using IMAC and
eluting isocratically with 1 M imidazole. After dialysis to
remove imidazole and the transition to thrombin cleavage
buﬀer, biotinylated thrombin was added to liberate VN
fragments from His-tagged thioredoxin. Thrombin was
removed by incubation with streptavidin agarose beads
followed by gel ﬁltration. Final puriﬁcation of the properly
disulﬁde-bonded VN fragments was accomplished using an
active PAI-1 aﬃnity column. The column contained active PAI1 with a single tryptophan to phenylalanine mutation at residue
175, located in the loop C-terminal of s3A. This mutant form of
PAI-1 remains active 3−4-fold longer than wtPAI-1 but
maintains similar thermodynamic characteristics.34 The capacity
of these constructs to inhibit binding of wild-type PAI-1 to

immobilized VN was determined with surface plasmon
resonance using a CM5 chip.12
Hydrogen/Deuterium Exchange Reactions. Proteins
were diluted into a preincubation buﬀer, containing 5 mM
MOPS, 100 mM (NH4)2SO4, 6.5 mM NaCl, 2 mM sodium
acetate, and 0.1 mM EDTA (pH 7.4) at 25 °C. This yielded
PAI-1 at 5 μM, wherein the buﬀering and salt components were
balanced to an identical composition among all experimental
permutations. This allowed complex formation and/or quick
exposure to Cu(II) ions prior to addition of deuterium (D2O)
buﬀer. For the copper experiments, the buﬀer also included 215
μM CuSO4. The pH of this buﬀer was adjusted to 7.4 at 25 °C
using NaOH after copper addition. Because buﬀers exhibit
signiﬁcant binding of metals, we have relied on known metal/
buﬀer binding constants, as described in our previous work.26
Using known ﬁrst-sphere buﬀer/metal ion aﬃnity values,
β1,36−38 the dissociation constant for metal ions in MOPS
was calculated using the equation 10β1 = Ka, where Ka = 1/Kd.
First-sphere MOPS/Cu(II) aﬃnity β1 equals 4.00.36 The free
metal ion concentration was then determined using the
quadratic equation Mf = Mt − {Mt + Bt + Kd − [(Mt + Bt +
Kd)2 − 4BtMt]1/2}/2, where Mf is the free metal concentration,
Mt is the total metal ion concentration, Bt is the total buﬀer
concentration, and Kd is the dissociation constant between the
metal ion and buﬀer. Note that EDTA is present to prevent
trace metal ion eﬀects and for protein stability; it was
subtracted from the total metal concentration before the free
metal ion calculation. For experiments including the SMB
domain, there was a 2-fold molar excess (10 μM) relative to the
PAI-1 concentration. Preincubation solutions (8 μL) were
diluted 20-fold (ﬁnal volume of 160 μL) into deuterium buﬀer
[5 mM MOPS, 100 mM (NH4)2SO4, 6.5 mM NaCl, 2 mM
sodium acetate, and 0.1 mM EDTA (pD 7.8) at 25 °C] and
incubated at 25 °C, and time point samples (10, 30, 180, and
600 s) were obtained by quenching with 1.38% (3.2 μL) formic
acid and ﬂash-freezing in liquid nitrogen.
Quenched samples were subjected to proteolytic digestion
using 16 μL of pepsin (ﬁnal concentration of 0.5 mg/mL) for 2
min on ice prior to injection. The entire sample was
immediately injected using an ice-cold Hamilton syringe into
a cooled Acquity HDX liquid chromatography system (Waters,
Milford, MA). Peptides were loaded onto a Vanguard BEH
C18, 2 mm × 5 mm precolumn (Waters) with a ﬂow rate of
300 μL/min and then eluted through an Acquity BEH 1 mm ×
100 mm C18 analytical column using a gradient of 8 to 15% B
over 0.5 min, 15 to 35% B over 5.5 min, and 35 to 85% B over
0.5 min at a ﬂow of 40 μL/min into the mass spectrometer.
Peptide ions were analyzed on a Waters Synapt G1 quadrupole
time-of-ﬂight (Q-TOF) mass spectrometer. The instrument
was calibrated daily to 3 ppm accuracy or lower. Undeuterated
wild-type and mutant PAI-1 were subjected to tandem (MS2)
CID fragmentation to identify each peptic peptide to be
analyzed using MASCOT (Matrix science). The average mass
of each peptide in every experimental run was calculated by the
following equation: average mass = ∑i(miIi)/(∑iIi), where i is
the isotope peak and runs from 1 to the total number of isotope
peaks in the isotopic envelop, Mi is the centroid mass of isotope
peak i, and Ii is the intensity of isotope peak i.
Deuterium uptake plots were generated by plotting the
average mass shift for each peptide against the logarithm of the
incubation time. Normalized uptake was calculated from
experimental samples with respect to fully deuterated controls
(100%). Fully deuterated control peptides were generated by
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incubation of PAI-1 in 4 M deuterated guanidinium chloride in
D2O for 4 h, followed by identical reaction quenching,
treatment, and analysis. Each protected amide hydrogen in a
protein can be found in a closed, open, or exchanged state
(closed ↔ open → exchanged), where closed and open refer to
cases in which the amide hydrogen participates in a hydrogen
bond and does not, respectively. The rate of opening is kopen,
while the rate of closing is kclose; the rate of hydrogen/
deuterium exchange when the amide hydrogen is in the open
state is kch (ch for chemical exchange rate). The EX2-type
exchange limit (EX2 kinetics) is deﬁned as the limit at which
the rate of closing is much faster than the rate of chemical
exchange, or kclose ≫ kch. EX2 kinetics is the most common type
of exchange observed in well-folded proteins. In this regime,
many opening events are required for each exchange event, and
the result is a gradual mass shift of one isotope population in
the spectra as a function of isotope exchange time. The EX1
exchange limit (EX1 kinetics) is deﬁned as the limit at which
the chemical exchange rate is much higher than the rate of
closing, or kch ≫ kclose. In this regime, the overall rate of
deuterium incorporation becomes equal to kopen. EX1-type
exchange kinetics is less commonly observed, but when it
occurs, it yields characteristic broadening of the isotopic
distribution or even a bimodal isotope distribution reﬂecting an
unfolding event. If isotope populations in such a bimodal
distribution are suﬃciently separated in mass (deuterium
content), it is possible to deduce the rate of unfolding as it is
equal to the rate at which the low-mass population interchanges
with the high-mass population. For a further explanation of
EX1 and EX2 kinetics, see ref 39.
Isothermal Titration Calorimetry (ITC). ITC directly
detects the heat exchange in a protein−ligand interaction to
determine enthalpy changes (ΔH), stoichiometries (n), and the
dissociation constant (Kd) of interaction. For ITC experiments,
PAI-1 and SMB domain stocks were buﬀer exchanged into 50
mM MOPS and 250 mM (NH4)2SO4 (pH 7.4) at 10 °C. To
achieve buﬀer matching of PAI-1 and copper(II) solutions,
PAI-1 was dialyzed for 2 h under the aforementioned buﬀer
conditions, and copper(II) solutions (300 μM) were made
from the dialysate. Addition of copper(II) sulfate resulted in a
drop in pH, so solutions were adjusted back to pH 7.4 at 10 °C
using NaOH. ITC was performed using 20 μM W175F PAI-1,
with and without 1.2 molar equivalents of the SMB domain (24
μM). Protein samples (2.2 mL) and copper(II) samples (4 mL)
were degassed for 5 min at 10 °C prior to being loaded into the
Microcal VP-ITC instrument. The PAI-1 sample was loaded
into the 1.394 mL volume ITC cell, for which the baseline
temperature was set to 10 °C for the entirety of the experiment.
The copper(II) solution was loaded into the syringe and
injected into the cell in 54 increments. Each injection was 5 μL
in volume, over 2 min intervals, using a total of 54 total
injections. Control experiments in which the copper solution of
the same concentration (300 μM) was injected into buﬀer in
the ITC sample cell were performed. The heats of each
injection in the control experiment were subtracted from the
data from experiments that included protein. The data were
then baseline-corrected using NITPIC software (University of
Texas Southwestern Medical Center, Dallas, TX) prior to data
analysis. The data were ﬁt to a two-site nonsymmetric binding
model using SEDPHAT (National Institutes of Health,
Bethesda, MD).

Article

RESULTS

Adaptation of the HDX-MS Method Is Needed To
Measure Metal Ion Eﬀects. The previous HDX-MS work
using N-terminally histidine-tagged PAI-1 and phosphatebuﬀered saline (PBS)31 employed unsuitable conditions for
these metal ion studies of wild-type PAI-1. We have expressed
PAI-1 without the N-terminal histidine tag, as it introduces an
engineered metal-binding site that is non-native to PAI-1. In
our previous work on metal ion eﬀects with PAI-1,12,26 we
avoided using PBS because the phosphate salts of the metal
ions have very low solubility and adopted therefore either a Tris
or MOPS buﬀer system. Furthermore, buﬀers have been
observed to have modest eﬀects on the stability of PAI-1, but
more importantly, buﬀers have widely varying aﬃnities for
metal ions themselves.26 MOPS buﬀer proved to be preferable
in previous stopped-ﬂow kinetic measurements because of the
tight binding exhibited by copper(II) and PAI-1,26 so this was
the buﬀer of choice for the HDX experiments.
We thus determined whether experimental conditions using
MOPS and wild-type PAI-1 yield reproducible HDX results
compared with previous work.31,33 HDX was performed on
wild-type PAI-1 and histidine-tagged PAI-1 in both PBS and
MOPS buﬀer for comparison. We observed that the presence
or absence of an N-terminal histidine tag has no eﬀect on PAI-1
dynamics in each buﬀer; results for all peptides were compared,
and peptide 64−92 (hD-S2A) is shown as an example from the
data set (Figure S1). While the HDX results were comparable
in PBS buﬀer for both forms of PAI-1, a surprising 20%
reduction in the level of deuterium uptake was generally
observed using the MOPS buﬀer system. We attribute this
reduction in the level of D uptake to the presence of the
ammonium sulfate component of the buﬀer, which is known to
have a stabilizing eﬀect on proteins. The only exception to this
trend was observed with highly dynamic peptides that were
fully deuterated within the experimental time frame.
Moreover, the reduction of the level of deuterium uptake in
MOPS versus PBS buﬀer oﬀers an advantage for observing
diﬀerences in HDX that will arise from ligands like Cu(II) that
increase protein dynamics. In PBS, many peptides reach fully
exchanged levels very quickly, so the dynamic range in HDX
experiments on PAI-1 is expanded using the MOPS buﬀer to
slow the exchange. However, a MOPS concentration of 50 mM
in the HDX-MS experiments caused severe chromatographic
interference during the reversed-phase chromatographic
separation of peptic peptides. The conditions ﬁnalized for
HDX-MS experiments therefore used 5 mM MOPS at 25 °C,
yielding conditions with a longer half-life for PAI-1 (t1/2 = 257
± 11 min) as expected because of temperature eﬀects. The
separate eﬀects of Cu(II) and the SMB domain on PAI-1 in 5
mM MOPS buﬀer at 25 °C are qualitatively similar to those
reported in Tris buﬀer, with t1/2 values of ∼418.3 ± 13 min for
PAI-1 with the SMB domain, ∼49.3 ± 6 min for PAI-1 with
Cu(II), and 424.7 ± 50 min for PAI-1 with the SMB domain
and Cu(II). Unexpectedly, the diﬀerence in half-life comparing
the conditions with the SMB domain versus the SMB domain
with Cu(II) was negligible. Thus, these experimental conditions
for HDX-MS are optimal for measuring diﬀerences in exchange
upon Cu(II) binding versus SMB domain binding but are not
sensitive for comparing the dynamic eﬀects of the SMB domain
versus the SMB domain with Cu(II). For the sake of
completeness, the half-life of PAI-1 was also measured at a
higher MOPS concentration of 50 mM (which is not suitable
4389
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Figure 2. Representative data from HDX-MS for active wtPAI-1. (a) Structure of PAI-1 showing the locations of three representative peptides. The
peptide spanning residues 46−59 of hB, hC, and the loop between them is colored orange. The peptide spanning residues 99−113 of the C-terminal
end of s2A, hE, and the loop between them is colored yellow. The peptide spanning residues 152−163 of the N-terminal part of s3A and part of the
preceding loop connected to hF is colored teal. (b−d) Representative deuterium uptake plots comparing the eﬀects of addition of Cu(II) (with or
without the SMB domain). Deuterium uptake plots are shown for three PAI-1 peptides: 46−59 (LQLTTGGETQQQIQ) in panel b, 99−113
(FVQRDLKLVQGFMPHF) in panel c, and 152−163 (LGKGAVDQLTRL) in panel d. HDX-MS experiments were conducted using wtPAI-1
(red), wtPAI-1 and Cu(II) (green), wtPAI-1 and the SMB domain (blue), and wtPAI-1, the SMB domain, and Cu(II) (purple). Deuterium uptake
plots show the increase in mass units for the individual peptides over time for the individual samples.

consistent with previous work,31 addition of the SMB domain
of VN resulted in widespread stabilization of the ﬂexible joint
region and the backside, constituting the majority of the lower
half of the molecule (Figure S2). In contrast, addition of Cu(II)
leads to increased exchange rates for peptides in many of these
regions. As shown in the representative plots in panels b and c
of Figure 2, addition of Cu(II) results in an increase in the level
of deuterium incorporation, consistent with increased dynamics
in regions covered by peptides 46−59 and 99−113, compared
with active wtPAI-1 alone. In line with previous reports,31
binding of PAI-1 by the SMB domain resulted in protection
against exchange, consistent with reduced structural dynamics
in the regions covered by these peptides. When both the SMB
domain and Cu(II) are added to PAI-1, similar results are
observed relative to the SMB domain addition alone for the
peptides displayed in Figure 2. Peptide 152−163 represents an
example of a peptide that is unaﬀected by the addition of
Cu(II) the presence or absence of the SMB domain (Figure
2d).
We observed numerous PAI-1 peptides that exhibited an
increase in the level of deuterium uptake as a result of Cu(II)
binding, and it was informative as a ﬁrst step to localize these
changes within the primary sequence of PAI-1. To facilitate this
analysis, the relative deuterium content, presented as a percent
of the full deuteration level, was calculated for each peptide,
with and without Cu(II) bound to PAI-1, and the diﬀerence in

for HDX-MS experiments). The eﬀects of Cu(II) and the SMB
domain on PAI-1 in 50 mM MOPS buﬀer at 37 °C are similar
to those reported in Tris buﬀer, with t1/2 values of 70.7 ± 3.6
min for PAI-1, 126.2 ± 4.3 min for PAI-1 with the SMB
domain, 38.3 ± 1.0 min for PAI-1 with Cu(II), and 170.9 ± 2.1
min for PAI-1 with the SMB domain and Cu(II). Interestingly,
under these conditions, Cu(II) causes a prolonged half-life of
PAI-1 when the SMB domain is bound, as reported
previously.12 The underlying reason for the diﬀerent eﬀects
of Cu(II) on the stability of PAI-1 under diﬀerent buﬀer
concentrations and temperature is not yet clear.
Addition of Copper(II) Increases Dynamics in Important Regions of PAI-1. The eﬀect of Cu(II) ions on the
backbone dynamics of active wtPAI-1 was probed in the
presence and absence of the SMB domain of VN. Deuterium
uptake plots for these experiments are presented in Figure S2.
Representative deuterium uptake plots are shown in Figure 2 to
illustrate the eﬀects of Cu(II) on three representative PAI-1
peptides generated by peptic cleavage. Unligated active wtPAI-1
is highly dynamic. Peptides comprising the lower backside
underlying the shutter (hB and hC), ﬂexible joint region (hD,
hE, and s1A), shutter region (s3A and s5A), and gate region
(s3C, s4C, and s3B) experience substantial deuterium uptake
over the experimental time course (Figure S2). Consistent with
previous work,31 the only regions predominantly protected
from exchange exist in β-sheet B in the protein core. Also
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Figure 3. Eﬀects of Cu(II) on PAI-1 dynamics via a look at the primary structure. HDX-MS data were collected for various exchange periods listed at
the far left. For each of the four time points, deuterium exchange is given as a percentage relative to that observed for wtPAI-1 alone. The data with
or without Cu(II) were normalized with respect to a (100%) fully deuterated control in which the protein is subjected to guanidine denaturation in
D2O for 4 h to determine the extent of deuterium exchange for unfolded protein. The primary structure of PAI-1 is shown along the top of each row,
with secondary structure elements noted as α-helices (green) and β-strands (blue). The identity of individual peptic peptides that were analyzed is
shown in the gray boxes along the sequence, and uptake results for each peptide at the four time points are shown in the columns below each
peptide. Note that the proteolysis yields peptides spanning most of the PAI-1 sequence, giving essentially complete coverage in the HDX-MS
experiments. The observed deuterium uptake values are the percentage diﬀerence between the two experimental conditions ([wtPAI-1 + Cu] −
[wtPAI-1 alone]). The normalized percent diﬀerence was color-coded as follows: dark blue for a percent diﬀerence of less than −20%, light blue for
−20 to 10%, white for −10 to 10%, orange for 10−20%, and red for >20%.

is apparent that Cu(II) binding increases dynamics in regions of
PAI-1 that are important for the anti-protease activity and
metastable nature of PAI-1, namely, the ﬂexible joint region and
underlying helices in the shutter region.
Binding of the SMB Domain Negates the Eﬀect of
Copper(II) on the Dynamics of PAI-1. Binding of PAI-1 by
the SMB domain from VN, which houses the primary highaﬃnity binding site for PAI-1,20 results in signiﬁcant protection
against exchange in several peptides, namely, 46−59 (hB−hC),
99−113 (s2A−hE), 114−128 (hE−s1A), and 299−306 (hI
loop−s5A) (Figures S2 and S3). This is consistent with
previously published results,31 although the SMB domain eﬀect
is generally less pronounced in this study because of the
reduced dynamics of PAI-1 in MOPS buﬀer compared to that
in PBS. The noted peptides are located in or proximal to the
ﬂexible joint region, including the SMB domain-binding
interface. Likewise, binding of both Cu(II) and the SMB
domain produced similar patterns of HDX protection observed
upon the binding of the SMB domain alone, a general
phenomenon illustrated by the examples in panels b and c of
Figure 2. As observed with binding of the SMB domain alone,
peptides 47−59 (hB−hC), 99−113 (s2A−hE), 114−128 (hE−
s1A), and 299−306 (hI loop−s5A) (Figures S2 and S3) are
regions highly protected from exchange when both the SMB
domain and Cu(II) are bound. Mapping of the results for

relative deuterium content was plotted as a heat map along the
primary sequence (Figure 3). Peptide 46−59 (hB−hC loop)
exhibited a high level of exchange in the presence of Cu(II),
indicative of an increase in dynamics in this region underlying
the shutter. Immediately following this peptide in the sequence,
peptides covering the ﬂexible joint region [64−94 (hC−hD),
99−113 (s2A−hE), 114−128 (hE−s1A), and 139−151 (hF)]
also have increased exchange consistent with elevated
dynamics. In addition, peptides spanning residues 284−298
(s6A−hI) and 299−306 (loop between hI and s5A),
immediately preceding the shutter region strand 5A, feature
increased dynamics as a result of Cu(II) binding. Importantly,
Cu(II) binding has no eﬀect on exchange in several regions of
PAI-1. Peptides covering the ﬁrst two N-terminal peptides that
include hA and the preceding N-terminal residues, β-sheets B
and C, hG, hH, and the C-terminus are unaﬀected by Cu(II)
binding in our measurements. To interpret the spatial signature
of Cu(II) binding on PAI-1 dynamics, we transferred the heat
map shown in Figure 3 onto the three-dimensional structure of
PAI-1 (Figure 4a). Each of the peptic peptides aﬀected by
Cu(II) addition is localized to the ﬂexible joint region and areas
underlying the shutter strands of β-sheet A. Altogether, our
observations using these experimental conditions indicate that
Cu(II) binding causes localized rather than global changes in
PAI-1 dynamics, on the time scale investigated. Furthermore, it
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behavior in PAI-1 upon binding of the combination of the SMB
domain and Cu(II), the experiments conducted here may not
reveal these. The lower exchange rate in MOPS at 25 °C, under
conditions geared to probe Cu(II) binding eﬀects and increases
in dynamics, is suboptimal for detecting further decreases in
dynamics beyond those invoked by binding of the SMB domain
alone. Taken together, our data show that both with and
without Cu(II), the binding of the SMB domain protects
against dynamic changes that are correlated with the
accelerated latency conversion that is induced upon the binding
of Cu(II) alone.
Importantly, the high aﬃnity of Cu(II) for PAI-1, previously
measured with a Kd of <100 nM,26 appears to be unaﬀected
upon the binding of the SMB domain. This is apparent from
isothermal titration calorimetry experiments (Figure S4) in
which the Cu(II) binding isotherm is unchanged comparing
PAI-1 and the PAI-1−SMB domain complex. Our ongoing
work has demonstrated that there are multiple binding sites for
metal ions on PAI-1, including two high-aﬃnity sites. The ﬁt to
the ITC data in Figure S4 shows that these two high-aﬃnity
binding sites, each with a Kd of <30 nM, remain unperturbed in
the presence of the bound SMB domain. Also, there is no
binding of Cu(II) to the isolated SMB domain detected by
calorimetry (not shown). Thus, the changes in dynamics
observed in these HDX experiments are due to binding and
conformational eﬀects of the SMB domain and Cu(II) and not
to changes in aﬃnity, which would alter saturation levels.
Furthermore, it is clear that the changes in HDX observed in
the presence and absence of the SMB domain are not due to
competition for metal binding.
Copper(II) Aﬀects Protein Dynamics in the Same
Regions within H2AH3A-PAI-1 and Wild-Type PAI-1. As
the recent crystal structure of W175F PAI-1 revealed a zinc
positioned proximal to the two N-terminal histidines of PAI-1
at positions 2 and 3 in the protein chain (PDB entry 3Q02),
experiments were designed to assess whether Cu(II) asserts its
eﬀect on PAI-1 dynamics through binding to these same
residues. A form of PAI-1 was engineered with alanine
substitutions for these two histidines, and HDX experiments
were performed to test for the eﬀects of Cu(II) on dynamics.
The representative uptake plot in panels a and b of Figure 5
compares H−D exchange rates for active wtPAI-1 with those
for active H2AH3A-PAI-1 in the presence and absence of
Cu(II). Data are shown for peptides 46−59 (hB−hC loop) and
99−113 (hE−s1A) as illustrative examples. Uptake plots for the
entire set of HDX measurements with H2AH3A-PAI-1 with
and without addition of Cu(II) are shown in Figure S5.
Comparing wild-type PAI-1 to H2AH3A-PAI-1 revealed a
decrease in HDX rates as a result of incorporation of this
double amino acid substitution into PAI-1 (Figure 5a,b). Also,
as with wild-type PAI-1, the mutant shows an increase in the
rate of deuterium exchange in the presence of Cu(II) compared
with that of H2AH3A-PAI-1 alone. Across the primary
sequence, changes in dynamics due to Cu(II) addition occur
in similar regions seen with active wild-type PAI-1 upon Cu(II)
binding (Figure S6). The regions that experience changes are
apparent when the Cu(II) eﬀects are mapped onto the
structure of H2AH3A-PAI-1 (Figure 5c). The peptides
spanning the hB−hC loop, hD, hE, hF, hI, and s5A all have
increased rates of exchange due to Cu(II) addition, as observed
with wild-type PAI-1 (Figure 4a).
From a structural perspective, mutant and wild-type PAI-1
are aﬀected by Cu(II) in largely similar regions, including the

Figure 4. Cu(II) increases localized dynamics in the ﬂexible joint
region and underlying shutter helices, and the SMB domain negates
the Cu(II) eﬀects. (a) Heat map of eﬀects of Cu(II) on the PAI-1
structure. The normalized percent diﬀerence in deuterium uptake
comparing wtPAI-1 and Cu(II) versus wtPAI-1 alone for the peptic
peptides (Figure 3) was mapped onto the three-dimensional structure
of active PAI-1 (PDB entry 3Q02). The percent diﬀerence in
deuterium uptake is shown for the 180 s HDX time point, colored
dark blue for less than −20%, light blue for −20 to −10%, dark gray
for −10 to 10%, orange for 10−20%, and red for >20%. Areas of light
gray represent peptides for which there was no sequence coverage. (b)
Heat map of eﬀects of Cu(II) and the SMB domain on the PAI-1
structure. The normalized percent diﬀerence in deuterium uptake
comparing wtPAI-1 with the SMB domain and Cu(II) vs wtPAI-1
alone for peptic peptides (Figure S2) was mapped onto the threedimensional structure of active PAI-1 (PDB entry 3Q02). The percent
diﬀerence in deuterium uptake is shown for the 180 s HDX time point,
colored dark blue for less than −20%, light blue for −20 to −10%, dark
gray for −10 to 10%, orange for 10−20%, and red for >20%. Areas of
light gray represent peptides for which there was no sequence
coverage. (c) Heat map depicting eﬀects of Cu(II) with the SMB
domain compared to the binding of the SMB domain alone on the
PAI-1 structure. The normalized percent diﬀerence in deuterium
uptake comparing wtPAI-1 with the SMB domain and Cu(II) vs
wtPAI-1 and the SMB domain for peptic peptides (Figure S2) was
mapped onto the three-dimensional structure of active PAI-1 (PDB
entry 3Q02). The percent diﬀerence in deuterium uptake is shown for
the 180 s HDX time point, colored dark blue for less than −20%, light
blue for −20 to −10%, dark gray fr −10 to 10%, orange for 10−20%,
and red for >20%. Areas of light gray represent peptides for which
there was no sequence coverage.

binding of the SMB domain and Cu(II) shows similar
protection patterns observed with binding of the SMB domain
alone31 and shows reduced dynamics in the ﬂexible joint region
(Figure 4b).
However, some diﬀerences in exchange that distinguish
binding of the SMB domain alone from binding of the SMB
domain and Cu(II) were apparent. As shown in Figure 4c, the
N-terminal peptide (residues 1−15) was substantially protected
upon binding of both the SMB domain and Cu(II) in contrast
to the protection seen for the binding of the SMB domain
alone. The change in HDX exchange behavior observed upon
binding of the combination of the SMB domain and Cu(II) is
sublocalized to residues 8−15, which exhibits protection
(Figure S2). The N-terminal histidine residues in positions 2
and 3 constitute one of the Cu(II)-binding sites on PAI-1 (see
below), but binding of copper(II) to this peptide does not
perturb its exchange behavior. Indeed, it should be noted that
peptide 1−7 is not diﬀerentially aﬀected by binding of any of
the ligands, presumably because it is highly dynamic at the
extreme N-terminus of the protein. Although it is likely that
there are additional changes that lead to reduced dynamics
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Figure 5. Evaluating the eﬀects of addition of Cu(II) on H2AH3A-PAI-1 dynamics. (a and b) Deuterium uptake plots for two PAI-1 peptides in
H2AH3A-PAI-1 and wtPAI-1:(a) peptide 46−59 (LQLTTGGETQQQIQ) and (b) peptide 99−113 (FVQRDLKLVQGFMPHF). HDX-MS
experiments were conducted using wtPAI-1 (red), wtPAI-1 and Cu(II) (green), H2AH3A-PAI-1 (purple), and H2AH3A-PAI-1 and Cu(II)
(orange). Deuterium uptake plots show the increase in mass units for the individual peptides over time. (c) Heat map of eﬀects of Cu(II) on the
H2AH3A-PAI-1 structure. The normalized percent diﬀerence in deuterium uptake comparing H2AH3A-PAI-1 and Cu(II) vs H2AH3A-PAI-1 alone
for the peptic peptides (Figure S6) was mapped onto the three-dimensional structure of active PAI-1 (PDB entry 3Q02). The percent diﬀerence in
deuterium uptake is shown for the 180 s HDX time point, colored dark blue for less than −20%, light blue for −20 to −10%, dark gray for −10 to
10%, orange for 10−20%, and red for >20%. Areas of light gray represent peptides for which there was no sequence coverage. (d) Structural heat
map of H2AH3A-PAI-1 dynamics compared with that of wtPAI-1. The normalized percent diﬀerence in deuterium uptake comparing H2AH3A-PAI1 vs wtPAI-1 for the peptic peptides was mapped onto the three-dimensional structure of active PAI-1 (PDB entry 3Q02). The percent diﬀerence in
deuterium uptake is shown for the 180 s HDX time point, colored dark blue for less than −20%, light blue for −20 to −10%, dark gray for −10 to
10%, orange for 10−20%, and red for >20%. Areas of light gray represent peptides for which there was no sequence coverage. (e) Structural heat
map of eﬀects of Cu(II) on H2AH3A-PAI-1 compared with wtPAI-1. The normalized percent diﬀerence in deuterium uptake comparing H2AH3APAI-1 and Cu(II) vs wtPAI-1 and Cu(II) for the peptic peptides was mapped onto the three-dimensional structure of active PAI-1 (PDB entry
3Q02). The percent diﬀerence in deuterium uptake is shown for the 180 s HDX time point, colored dark blue for less than −20%, light blue for −20
to −10%, dark gray for −10 to 10%, orange for 10−20%, and red for >20%. Areas of light gray represent peptides for which there was no sequence
coverage.

ﬂexible joint region and helices that border the shutter region,
although there are some diﬀerences. Figure 5d shows the
diﬀerence in dynamics comparing H2AH3A-PAI-1 and wildtype PAI without ligands, and Figure 5e shows the diﬀerences
mapped onto the structure for the two forms of the protein
with added Cu(II). The decreased dynamics in H2AH3A-PAI-1
at multiple sites in the protein are apparent, in the presence or
absence of Cu(II). One intriguing diﬀerence of note between
the mutant and wild-type PAI-1 is observed with peptides 1−15
and 8−15 (hA) that include the mutated residues. These
peptides are protected from exchange in the presence of Cu(II)
and the SMB domain in wtPAI-1 but show no diﬀerences when
Cu(II) alone is added to wtPAI-1 (Figure S2). Conversely,
addition of Cu(II) results in an increase in the rate of exchange
for the same peptides in H2AH3A-PAI-1. Apart from this

diﬀerence, the overall response in dynamics to Cu(II) binding
is quite similar for wtPAI-1 and H2AH3A-PAI-1, suggesting
that the Cu(II)-induced destabilization is not mediated by the
binding of Cu(II) to the two N-terminal histidines of PAI-1.
Copper(II) Has Modest Eﬀects on the Dynamics of the
Latent Form of wtPAI-1. Previous binding studies showed
that metals bind to both the active and latent forms of PAI-1,
albeit with diﬀering aﬃnities.26 It is therefore important to
determine whether Cu(II) aﬀects the dynamics of both the
active and latent form of PAI-1. HDX studies were thus
pursued with latent wild-type PAI-1 in the presence and
absence of added Cu(II). In the absence of Cu(II), results from
peptides throughout PAI-1 illustrate an almost global reduction
in HDX rates that accompanies the conformational change to
the latent form, consistent with previous work,31 as shown in
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Figure 6. Local unfolding kinetics of PAI-1 peptide 46−63 accelerated in the presence of Cu(II). The isotopic envelopes for active wtPAI-1 alone
(left) and active wtPAI-1 and Cu(II) (right) are shown in duplicate for HDX time points 10, 30, 180, and 600 s. The data shown are from the peptic
peptide (residues 46−63), underlying shutter strands s3A and s5A, under both experimental conditions.

experiments conducted here were performed at 25 °C in
MOPS buﬀer and terminated after exchange for 10 min, we did
not sample the appropriate time and temperature to observe
the unfolding of regions covered by peptides 16−40 and 307−
340. The unfolding previously observed in the hB−hC peptide
was much more frequent and is therefore sampled in the
experiments conducted here (Figure 6). Interestingly, the
change to MOPS buﬀer decreased the rate of unfolding
signiﬁcantly, and only a negligible fraction of molecules have
visited the unfolded state after incubation for 10 min as judged
by the limited peak broadening. Most importantly, addition of
Cu(II) accelerates the unfolding event substantially (t1/2 ∼ 20
s), and the spacing between the two mass populations
resembles that previously observed when PAI-1 was analyzed
in PBS. This means that addition of Cu(II) not only
counteracts the eﬀect of MOPS on the rate of unfolding but
also forces the geometric extent of unfolding in the region to
revert to that observed in PBS. As expected, we also observed
this bimodal peak distribution in the mutant H2AH3A-PAI-1
(data not shown). Taken together, the correlation between
accelerated local unfolding and accelerated latency transition
upon addition of Cu(II) to PAI-1 further supports the
hypothesis that unfolding events contribute in signiﬁcant
ways to the mechanism by which active PAI-1 rearranges to
the latent inactive conformation.

the deuterium uptake for all peptides (Figure S7), also
illustrated by representative uptake plots of peptides 46−59
(hB−hC loop) and 99−113 (s2A−hE) (Figure S8), and the
map across primary sequence (Figure S9). The sample uptake
plots in Figure S8 compare active wtPAI-1 in the presence and
absence of Cu(II) with latent wtPAI-1 in the presence and
absence of Cu(II). A view of the eﬀect of Cu(II) on latent wildtype PAI-1 is illustrated by the three-dimensional rendering
shown in Figure S8. While there are modest changes in
dynamics for a few peptides, the diﬀerences are not localized to
one region on the structure; nor are they located in regions
known to inﬂuence latency conversion or protease inactivation.
Copper(II) Accelerates Local Unfolding of a Peptide in
the hB−hC Region on a Time Scale Relevant for the
Latency Transition. Recently, HDX-MS was used to reveal
local unfolding events in PAI-1 peptides that occur on time
scales relevant to latency conversion.18 The signature of an
unfolding event in the HDX-MS data is the presence of
bimodal isotope distributions (see Materials and Methods for
further explanation). In the case of a transient unfolding event,
protein molecules that have not yet visited the unfolded state
will yield a low-mass population in the mass spectrum, whereas
protein molecules that have visited the unfolded state will yield
a high-mass population. The mass diﬀerence between the two
populations is proportional to the number of backbone amide
hydrogens exposed to the solvent as a consequence of the
unfolding event. The rate of unfolding can be measured as the
rate at which the low- and high-mass populations interconvert.
Three peptides detected in the HDX-MS experiments on PAI-1
displayed this eﬀect: 46−63 (hB−hC) with a t1/2 of ∼80 s at 15
°C (<10 s at 37 °C), 16−40 (hA−s6B) with a t1/2 of ∼18 min
at 37 °C, and 307−340 (s5A) with a t1/2 of ∼24 min at 37 °C.18
Cu(II) binding increases the rate of the latency transition, and
we thus reasoned that Cu(II) might assert this eﬀect through
acceleration of these transient unfolding events. As the HDX

■

DISCUSSION
Copper(II) Increases Dynamics in Regions Similar to
Those Aﬀected by the SMB Domain. Cu(II) accelerates the
latency conversion of PAI-1, while the presence of the SMB
domain of VN negates the destabilizing eﬀect of Cu(II).
Because the SMB domain restricts dynamics of PAI-1,31 we
hypothesized that addition of Cu(II) would increase the level of
deuterium exchange if protein dynamics play an inﬂuential role
in the rate of conversion. This hypothesis is supported by the
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study (5 mM MOPS at 25 °C), no additional stabilization of
SMB domain-bound PAI-1 was observed upon ligation with
Cu(II). Nevertheless, the MOPS buﬀer system incurring a
general stabilizing structural eﬀect on PAI-1 slowed exchange
rates and narrowed the eﬀective window for measuring
decreases in HDX-MS, as expected upon binding the
combination of the SMB domain and Cu(II). Half-lives for
PAI-1 vary somewhat with buﬀering agents, but the observed
trends whereby the SMB domain of vitronectin decreases rates
of latency conversation are consistent.
N-Terminal Histidines of PAI-1 Do Not Mediate
Changes in Dynamics Aﬀected by Copper(II). We
previously identiﬁed the N-terminal histidines as well as gate
region (E212, D222, E350, and E242) carboxylates as potential
targets for metal coordination in the most recent PAI-1 crystal
structure determination.34 In this study, we tested the
hypothesis that Cu(II) binds at the N-terminal site and leads
to increases in dynamics. If the two histidines were critical for
coordinating Cu(II), then mutation of these residues would
eliminate Cu(II)-induced changes in the dynamics of PAI-1. An
interesting and unexpected result is the global reduction in
dynamics upon substitution of alanine for both histidine 2 and
histidine 3. Nonetheless, it was clear that H2AH3A-PAI-1
follows a pattern similar to that of the wild-type protein with
regard to dynamic changes in the presence of Cu(II).
Altogether, these data indicate that the N-terminal histidines
are not the residues that coordinate metal to produce elevated
dynamics and accelerated latency transition kinetics.
Latent wtPAI-1 Is Insensitive to the Eﬀects of
Copper(II) on Dynamics. A global reduction in dynamics
was observed upon comparison of active and latent PAI-1, due
to the conformational change that yields a more compact, rigid
structure. The only region with increased exchange in the latent
form of PAI-1 is in the gate region, due to the widening of βsheet C strands that is necessary to allow the RCL to pass
through during loop insertion. Addition of Cu(II) to latent
PAI-1 resulted in modest increases in the rate of exchange from
a few isolated peptides but had no eﬀect on the ﬂexible joint
region. Addition of Cu(II) had a minimal inﬂuence on
dynamics near the gate region, an area that opens as a result
of a conformational shift to the latent state. Although there
could be several reasons for these observations, the most likely
interpretation lies at the heart of the study. That is the
metastable nature of PAI-1 that keeps it poised for protease
inactivation and drives it toward a timed inactivation as it
converts to a latent form. Clearly, active PAI-1 is highly
dynamic and sensitive to ligands that promote changes in
protein dynamics that inﬂuence the overall conformation.
Latent PAI-1 is inherently restricted in dynamics and thus not
as prone to eﬀects upon ligand binding.
An Early Unfolding Event Related to the Latency
Transition. As mentioned above, the need to perform
experiments on Cu(II), a ligand that increases PAI-1 H−D
exchange rates, required a modiﬁcation of experimental
conditions (temperature and buﬀer) to slow the exchange
rates within a measurable window. This adjustment oﬀered an
opportunity for us to observe a local unfolding event that
occurs in the time frame of the experiment. This is local
unfolding of peptide 46−63 (hB−hC) that occurs with a t1/2 of
80 s at 15 °C and a t1/2 of <10 s at 37 °C in PBS buﬀer.18 The
observation of local unfolding in this region provides some
insight into the mechanism by which Cu(II) exerts its eﬀect
and promotes the conformational change toward latency. In

observation that the same PAI-1 regions that are stabilized by
SMB domain binding are the regions in which dynamics are
enhanced upon binding Cu(II). The ﬂexible joint region, gate
region, and shutter region are known to mediate steps in the
mechanism for the conformational transition of PAI-1 from the
active to latent form.12,26 We observed changes in dynamics in
largely overlapping regions aﬀected by binding of the SMB
domain as well as Cu(II), including the ﬂexible joint region, and
the N-terminal part of hF.13 We also observed changes due to
Cu(II) in the area underlying the shutter in the hB−hC peptide
and a proximal hI peptide. Importantly, the altered dynamics
did not manifest globally but were localized to key regions. In
other words, some dynamic, as well as protected, regions within
PAI-1 experienced no changes as a result of Cu(II) binding in
our experiments.
Metal ions have a unique eﬀect on PAI-1, characterized by
the ability to promote or prevent the latency transition at
higher buﬀer concentrations, depending on binding of the
cofactor vitronectin. The binding of Cu(II) accelerates the
latency transition12 and strongly increases the rate of HDX for
peptides spanning helices hB, hC, and hI. Although no other
ligands with this unusual property have been identiﬁed,
mutagenesis approaches have provided insights into the
importance of the shutter and the hB−hC peptide for the
latency transition. For example, amino acid substitutions that
disrupt a hydrogen bonding network in the shutter region
increase latency conversion rates,40 with altered sensitivity to
vitronectin as a stabilizing protein. Also, a substitution for K323
in β-strand 5A in the vicinity of the shutter resulted in
diﬀerential eﬀects in the presence and absence of vitronectin.40
Interestingly, monoclonal antibody binding can modulate the
vitronectin eﬀects in unexpected ways, particularly with the
K323A mutant.41 Previous biochemical and HDX studies using
the Mab-l antibody32 and aptamers24 designed to stabilize PAI1 in the active form targeted the ﬂexible joint region, but also
helices hB, hC, and hI of PAI-1.24 Addition of Mab-1 and
aptamers stabilized PAI-1 in the active form by 1.4-fold32 and
3−4-fold,24 respectively. Strikingly, peptides spanning this
region also exhibited decreased rates of exchange in the
presence of the Mab-1 antibody,31 aptamers,33 and the SMB
domain,31 albeit with diﬀering protection patterns for the
various ligands. Taken together with our data on copper(II) ion
eﬀects, these ﬁndings further support the hypothesis that
dynamics of hB, hC, and hI play a role in latency conversion33
Our results feature more protection than in previous studies,
caused by the buﬀer optimization from PBS to MOPS for metal
ion studies. This switch was vital for maintaining an appropriate
dynamic window for PAI-1 in the presence of a ligand that
increases the rate of exchange. In the previous studies
conducted in PBS, many peptides reached fully deuterated
levels within the ﬁrst time points.31 The propensity of
phosphate to precipitate divalent metal ions meant that PBS
was not an option for our studies and allowed us to observe
Cu(II) eﬀects that increased HDX rates relative to that of the
unligated protein. On the other hand, the slower exchange rates
in the MOPS buﬀer system limited our ability to measure
diﬀerences at the other extreme. For example, binding of the
SMB domain protected the ﬂexible joint region but was less
dramatic in MOPS relative to HDX with PAI-1 alone compared
to previous results in PBS.31 Upon binding to the SMB domain
and Cu(II) concurrently, PAI-1 remains in the active form
longer than with the SMB domain alone at 50 mM MOPS and
37 °C. However, using the conditions designed for the HDX
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regions of PAI-1. In a broader sense, our demonstration that
ligands have speciﬁc eﬀects on dynamics is particularly
intriguing in the case of a metastable protein that undergoes
a transition from active to inactive conformations readily under
physiological conditions. These speciﬁc eﬀects of Cu(II) on
PAI-1 provide a mechanistic understanding of the unusual
metal ion eﬀects, depending on vitronectin, which can aﬀect
activity in a variety of biological settings where metals and PAI1 are tied to disease.

our study, the same peptide (peptide 46−63) experiences local
unfolding, in MOPS buﬀer in 10 min at 25 °C, but the
experimental time scale would have to be extended to view the
local unfolding kinetics completely. The addition of Cu(II)
under these conditions decreased the t1/2 to ∼30 s. Because
PAI-1 has a half-life for conversion to the latent form (37 °C)
of approximately 1 h, with a decrease to 10 min upon binding
of Cu(II), these rates of local peptide unfolding observed by
HDX likely correspond to early events in the latency transition
process. The other peptides (16−40 and 299−306) have t1/2
values for unfolding on the order of that of the latency
transition process itself.18 It is important to note that we also
observe local unfolding in peptide 46−63 of H2AH3A-PAI-1
with Cu(II) bound, indicating that Cu(II) exerts it eﬀects on
PAI-1 by binding in positions diﬀerent from a site including the
two N-terminal histidines. Taken together, these results show
that Cu(II) binding facilitates an early transition presumed to
be on the pathway to latency.
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Representative deuterium uptake levels comparing the
deuterium uptake of PAI-1 with and without an Nterminal His tag in PBS buﬀer and MOPS buﬀer (Figure
S1), deuterium uptake plots of active wtPAI-1 in the
presence and absence of Cu(II) and the SMB domain
(Figure S2), determination of the eﬀect of the SMB
domain and Cu(II) on PAI-1 dynamics via a look at the
primary structure (Figure S3), binding of Cu(II) to
active PAI-1 determinied by ITC (with and without the
SMB domain) (Figure S4), deuterium uptake plots of
active wtPAI-1 versus H2AH3A PAI-1 in the presence
and absence of Cu(II) (Figure S5), eﬀect of Cu(II) on
H2AH3A-PAI-1 dynamics (Figure S6), deuterium uptake
plots of active wtPAI-1 versus latent wtPAI-1 in the
presence and absence of Cu(II) (Figure S7), latent
wtPAI-1 that features minimal changes in HDX in the
presence and absence of Cu(II) (Figure S8), and
determination of the eﬀect of Cu(II) binding on latent
PAI-1 dynamics via a look at the primary structure
(Figure S9) (PDF)
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CONCLUSIONS
The goal of this study was to evaluate the eﬀects of Cu(II) on
protein dynamics of several forms of PAI-1, including active
wild-type PAI-1, active PAI-1 in the presence of the SMB
domain, latent PAI-1, and active H2AH3A-PAI-1. PAI-1 works
in complex with VN at sites of vascular injury to regulate
hemostasis and also associates with the extracellular matrix
where it has been associated with normal and disease
pathologies, including inﬂammatory responses, tumor development, and obesity. Circulating, tissue, and extracellular reserves
of Cu(II) play roles in these pathophysiological situations that
are not well understood. Our recent discovery of unexpected
eﬀects of Cu(II) on PAI-1 activity and stability,12,26 in a
vitronectin-dependent fashion, prompted us to evaluate eﬀects
on protein dynamics that could be tied to function. Addition of
physiologically relevant concentrations of Cu(II), which
accelerate conversion of PAI-1 to its latent form, results in
increased dynamics of PAI-1 within regions similar to those that
exhibit decreased dynamics upon the binding of the SMB
domain of VN. Binding of both Cu(II) and the SMB domain
together negates Cu(II) eﬀects, resulting in patterns of
protection similar to those seen when the SMB domain alone
is bound. Because Cu(II) accelerates the latency transition, but
the SMB domain stabilizes the active form, these data on the
dynamic behavior of PAI-1 correspond nicely with the
measurement of PAI-1 latency conversion in the presence of
the ligands using kinetic approaches.12 In addition to many of
the known structural features of PAI-1 tied to conformational
stability, including the ﬂexible joint region, shutter region, and
gate region, the dynamics of helices hB, hC, and hI emerge as
important factors that determine the rate of latency conversion.
Furthermore, local unfolding observed in a peptide spanning
hB and hC occurs with a half-life that is accelerated in the
presence of Cu(II). The time scales indicate this local unfolding
event occurs early in the latency conversion process.
Observation of the unfolding upon Cu(II) addition suggests
that PAI-1 employs a similar path to the latent state in the
presence and absence of Cu(II). This study indicates that
protein dynamics guide the PAI-1 latency conversion process.
Comparing and contrasting among ligands that stabilize and
destabilize PAI-1 show that they decrease and increase
dynamics, respectively. Thus, physiologically important metal
ion ligands that alter the latency transition in a VN-dependent
manner eﬀect changes by altering protein dynamics in key
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